Elevated Plasma sVCAM-1 Levels in Children With Sickle Cell Disease: Impact of Chronic Transfusion Therapy

American Journal of Hematology

Volumn 76, Issue 1, 2004, Pages 57-60

  Sakhalkar, Vishwas S ^a,c   Rao, Sreedhar P ^b   Weedon, Jeremy ^b   Miller, Scott T ^b  

^a Department of Pediatrics   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Acute chest syndrome; Acute pain episode; Chronic transfusion therapy; Sickle cell anemia; Vascular cell adhesion molecule 1; White blood cell count

Indexed keywords

SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CHEST SYNDROME; ACUTE PAIN EPISODE; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PAIN; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CHEST PAIN; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; TIME FACTORS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 2342476596     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20016     Document Type: Article

References (25)

1. Serjeant GR. Sickle cell disease. Lancet 1997;350:725-730.
2. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: Clinical presentation and course. Co-operative Study of Sickle Cell Disease. Blood 1997;89:1787-1792.
3. Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996;88:2311-2320.
4. Shiu Y, Udden MM, McIntire LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 2000;95:3232-3241.
5. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999;94:1555-1560.
6. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM. Reticulocytes from patients with sickle cell anemia express α4β1-integrin complex and bind to TNF-α stimulated endothelial cells via a VCAM-1-α4β 1-dependent mechanism. Blood 1993;82:1891-1899.
7. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of VCAM-1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-1211.
8. Natarajan M, Udden MM, McIntire LV. Adhesion of sickle red blood cells and damage to interleukin-1β stimulated endothelial cells under flow in vitro. Blood 1996;87:4845-4852.
9. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5-11.
10. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the stroke prevention trial in sickle cell anemia (STOP). J Pediatr 2001;139:785-789.
11. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994;125:909-911.
12. Dover GJ, Platt OS. Sickle cell disease. In: Nathan DG, Orkin SH, editors. Hematology of infancy and childhood. Vol 1. Philadelphia, PA: W.B. Saunders; 1998. p 762-809.
13. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle cell anemia. A possible determinant of disease severity. N Engl J Med 1980;302:992-995.
14. Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol 1996;3:118-124.
15. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 1996;81:96-98.
16. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. New Engl J Med 1994;330:733-737.
17. Bernini JC, Rogers ZR, Sandler ES, Reisch JR, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome. Blood 1998;92:3082-3089.
18. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1937-1941.
19. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984;63:162-169.
20. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med 1991;325:11-16.
21. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-649.
22. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992;120:360-366.
23. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
24. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-508.
25. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-89.